Long-term HIV and tuberculosis outcomes in co-infected patients with treatment limiting severe cutaneous adverse reactions

Veenstra, Simon

Long-term HIV and tuberculosis outcomes in co-infected patients with treatment limiting severe cutaneous adverse reactions

Thesis / Dissertation

2023

Abstract

Background Treatment-limiting severe cutaneous adverse reactions (SCAR) occur more commonly amongst persons co-infected with tuberculosis (TB) and advanced HIV. The impact of SCAR on long-term HIV and TB outcomes is unknown. Methods Patients with active TB and/or HIV admitted to Groote Schuur Hospital, Cape Town, South Africa with SCAR between 1/10/2018 and 30/09/2021 were eligible. Clinical and laboratory follow-up data was collected for 6 and 12-month outcomes: mortality, TB and antiretroviral therapy (ART) regimen changes, TB treatment completion, and CD4 count recovery. Results Forty-eight SCAR admissions included: 34, 11, and 3 HIV-associated TB, HIV-only and TB-only patients with 32, 13 and 3 cases of drug reaction with eosinophilia and systemic symptoms, StevensJohnson syndrome/toxic epidermal necrolysis and generalised bullous fixed drug eruption respectively. Nine (19%), all HIV-positive, were deceased at 12-months, and 12 (25%) were lost to all care levels. Amongst TB-SCAR patients, seven (21%) were discharged on all four first-line anti-TB drugs (FLTD), while 12 (33%) had discharge regimens with no FLTDs; 24/37 (65%) completed TB treatment. Amongst HIV-SCAR patients, 10/31 (32%) changed ART regimen. If retained in care (24/36), median (IQR) CD4 counts increased by 12-months post-SCAR (115 (62-175) vs. 319 (134-439) cells/uL). Conclusion SCAR admission amongst patients with HIV-associated TB results in substantial mortality, and considerable treatment complexity. However, if retained in care, TB regimens are successfully completed, and immune recovery is good despite SCAR.

Keywords

Internal Medicine

Reference:

Collections

Masters

Full item page